Compare Exelon Corporation Common Stock (EXC) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Exelon Corporation Common Stock vs Tango Therapeutics Inc. — how do they compare? Exelon Corporation Common Stock trades at $43 (market cap $43.61B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Exelon Corporation Common Stock is far larger — about 11.6× Tango Therapeutics Inc.'s market cap, and Exelon Corporation Common Stock pays a 3.97% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals.
| EXC | TNGX | |
|---|---|---|
Market Cap | $43.61B | $3.75B |
Volume | 5,642,975 | 9,619,106 |
Sector | Utilities | Health |
52-Week High | $50.29 | $32.90 |
52-Week Low | $40.20 | $7.50 |
Enterprise Value | $94.47B | $2.77B |
Dividend Yield | 3.97% | — |
Typical Hold Time | — | 0 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Exelon (EXC) trades at $42.34, up 0.52% today, with a mixed technical picture showing a bullish overall signal but bearish moving averages and oscillators. The company reported strong earnings beats in recent quarters except for a Q2 2026 miss, with Q3 2026 results expected on October 30, 2026. Financials show solid profitability with a 10.99% net income margin and a P/E of 15.56, while cash flow trends indicate improving operational performance.
The outlook is cautiously optimistic, supported by a $48.11 analyst consensus price target and institutional accumulation, but risks include regulatory approvals for dividends and high RSI levels suggesting overbought conditions. Earnings growth and grid investment plans are key catalysts, though investor sentiment remains divided amid rate environment uncertainties.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Exelon Corporation Common Stock
Exelon is the parent company of six regulated electric and natural gas utilities. Its utilities include Atlantic City Electric, BGE, ComEd, Delmarva Power, PECO, and Pepco.
Read more on EXC →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
